SILLAJEN

“A global leader in oncolytic immunotherapeutics” Targeting, Attacking, and Eradicating Cancers^®
“A global leader in oncolytic immunotherapeutics” Targeting, Attacking, and Eradicating Cancers^®
“A global leader in oncolytic immunotherapeutics” Targeting, Attacking, and Eradicating Cancers^®

Notice & News

SillaJen Announces First Patient Enrolled in Part 2 of Renal Cell Carcinoma Trial with Pexa-Vec in Combination with Regeneron's Libtayo® (cemiplimab-rwlc) 첨부이미지

SillaJen Announces First Patient Enrolled in Part 2 of Renal Cell Carcinoma Trial with Pexa-Vec in Combination with Regeneron's Libtayo® (cemiplimab-rwlc)

SillaJen and Lee's Pharmaceutical Announce First Patient Enrolled in the PHOCUS Trial in China Phase 3 Clinical Trial for Oncolytic Immunotherapy, Pexa-Vec, in Liver Cancer 첨부이미지

SillaJen and Lee's Pharmaceutical Announce First Patient Enrolled in the PHOCUS Trial in China Phase 3 Clinical Trial for Oncolytic Immunotherapy, Pexa-Vec, in Liver Cancer

SillaJen and Lee's Pharmaceutical Announce First Patient Enrolled in the PHOCUS Trial in China Phase 3 Clinical Trial for Oncolytic Immunotherapy, Pexa-Vec, in Liver Cancer

SillaJen Announces First Patient Enrolled in Renal Cell Carcinoma Trial with Pexa-Vec in Combination with Regeneron’s Cemiplimab 첨부이미지

SillaJen Announces First Patient Enrolled in Renal Cell Carcinoma Trial with Pexa-Vec in Combination with Regeneron’s Cemiplimab

SillaJen Announces First Patient Enrolled in Renal Cell Carcinoma Trial with Pexa-Vec in Combination with Regeneron’s Cemiplimab

SillaJen Poster Presentation at 2018 GU ASCO Symposium Highlights New Clinical Data in RCC, Intravenous Delivery of Pexa-Vec, Oncolytic Immunotherapy 첨부이미지

SillaJen Poster Presentation at 2018 GU ASCO Symposium Highlights New Clinical Data in RCC, Intravenous Delivery of Pexa-Vec, Oncolytic Immunotherapy

SillaJen Poster Presentation at 2018 GU ASCO Symposium Highlights New Clinical Data in RCC, Intravenous Delivery of Pexa-Vec, Oncolytic Immunotherapy

Main Pipeline

대표연구

Pexa-Vec

Pexa-Vec is the most advanced product candidate. Pexa-Vec is engineered to selectively infect and replicate in cancer cells by exploiting the genetic changes that frequently occur in cancer cells.

대표연구

JX-970

JX-970 is next generation pipeline. In preclinical studies, JX-970 exerted tumor debulking effect and the same time demonstrated selective preference for tumor tissues.

Pexa-Vec Mechanism of Action

Pexa-Vec (JX-594)

펙사벡 작용기전 영상 보기

펙사벡 작용기전 영상 보기

Investor Relations

Partnership

SillaJen is actively seeking development partners and/or licensing opportunities for all of its assets.

OFFICE

SillaJen Headquarter

SillaJen Head Office

서울지사

109, Sogong-ro, Jung-gu, Seoul, Republic of Korea (ZIP Code : 04525) +82 (2) 368-2600 +82 (2) 783-7555

Busan Office

SillaJen Busan Office

부산본사

6F, 111, Hyoyeol-ro, Buk-gu, Busan, Republic of Korea (ZIP Code : 46508) +82(51) 517-7550 +82(51) 517-7558

Pangyo Office

SillaJen Research Center

연구소

San Francisco Office

Sillajen Biotherapeutics Office

샌프란시스코 자회사

SillaJen Biotherapeutics 475 Sansome St, Suite 740 San Francisco, CA 94111 +1-415-281-8886